OCA
MREO

Octagon Capital Advisors’s Mereo BioPharma MREO Stock Holding History

Octagon Capital Advisors’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000,000
Closed -$750K – 40
2022
Q4 		$750K Hold
1,000,000
– – 0.12% 30
2022
Q3 		$861K Hold
1,000,000
– – 0.15% 32
2022
Q2 		$1.12M Buy
+1,000,000
New +$775K 0.3% 19

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Octagon Capital Advisors's MREO Position: Q1 2023 in Review

Octagon Capital Advisors sold out of Mereo BioPharma (MREO) in Q1 2023, closing a stake of 1,000,000 shares — an estimated $750K sold.

Octagon Capital Advisors first reported a position in MREO in Q2 2022 and held it in 3 quarters. The position peaked at $1.12M in Q2 2022. 58 funds tracked by Wall St. Rank hold MREO as of Q1 2023.

  • Octagon Capital Advisors reported no remaining Mereo BioPharma position as of Q1 2023 after selling out during the quarter.
  • Octagon Capital Advisors sold 1,000,000 Mereo BioPharma shares in Q1 2023, an estimated $750K.
  • Octagon Capital Advisors first reported a position in Mereo BioPharma in Q2 2022 and held it in 3 quarters.
  • Octagon Capital Advisors's Mereo BioPharma position peaked at $1.12M in Q2 2022.
  • 58 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2023.

Based on Octagon Capital Advisors's 13F filing for Q1 2023, filed 15 May 2023.